The BAM Connection, an independent Brooklyn-based advertising, branding and content creation agency, today announced it has been selected as the Agency of Record (AOR) for Keystone Canna Remedies (KCR), Pennsylvania’s first medical marijuana dispensary. The account will be run by Maureen Maldari, CEO of The BAM Connection.
Starting immediately, the agency will be handling a variety of creative work for the company, including digital, video and social media, as well as overseeing strategy.
“We are incredibly excited for this partnership and to tackle the challenges of a new category,” said Maldari. “We have a wide breadth ofcombined health and wellness experience, but this is uncharted territory that we’re looking forward to navigating together to help Keystone Canna Remedies achieve their mission of a pain-free Pennsylvania.”
Keystone Canna Remedies has created a business model which allows patients to take an active role in their own health maintenance. The company was formed when its founding partners witnessed how medical marijuana can ease suffering across a broad spectrum of afflictions.
“The BAM Connection’s innovative yet simplistic approach were extremely appealing to us,” said Victor Guadagnino, Chief Business Development Officer at Keystone Canna Remedies. “As Pennsylvania’s first medical marijuana dispensary, we needed a strong creative partner to get the word out about our business, and we think Maureen and Rob’s team will definitely help us to break through to reach our intended audiences in exciting ways.”
Both Maldari and her business partner Chief Creative Officer Rob Baiocco are highly-regarded creative heavyweights with broad experience in the advertising industry. Since opening in 2013, The BAM Connection has grown steadily by challenging the complexity of agency models with its tenacious belief that ‘Simplicity liberates Creativity.’
Today’s announcement comes on the heels of the recent news that The BAM Connection was selected to begin work for the AmLactin®portfolio of skin care brands, part of Sandoz, a division of the Novartis Group.